$TRVI News

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target

Trevi Therapeutics, Inc. (TRVI) Analyst/Investor Day - Slideshow

Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030

Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary

Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030

HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target

Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23

Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript

Trevi Therapeutics Q1 Earnings Call Highlights

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Trevi Therapeutics Q1 2026 Earnings Call Transcript

Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate

Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

Trevi Therapeutics to Participate in Upcoming May Events

Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Trevi Therapeutics: Late-Stage Transition Meets Execution Risk